These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2. Xu F, Leadon SA, Yu Y, Boyer CM, O'Briant K, Ward K, McWatters A, Zhao X, Bae DS, DeSombre K, Zalutsky MR, Bast RC. Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821 [Abstract] [Full Text] [Related]
25. Bioavailability of recombinant tumor necrosis factor determines its lethality in mice. Ameloot P, Takahashi N, Everaerdt B, Hostens J, Eugster HP, Fiers W, Brouckaert P. Eur J Immunol; 2002 Oct; 32(10):2759-65. PubMed ID: 12355427 [Abstract] [Full Text] [Related]
26. Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window. Shibata H, Yoshioka Y, Ikemizu S, Kobayashi K, Yamamoto Y, Mukai Y, Okamoto T, Taniai M, Kawamura M, Abe Y, Nakagawa S, Hayakawa T, Nagata S, Yamagata Y, Mayumi T, Kamada H, Tsutsumi Y. Clin Cancer Res; 2004 Dec 15; 10(24):8293-300. PubMed ID: 15623605 [Abstract] [Full Text] [Related]
29. Dual regulation of soluble tumor necrosis factor-alpha induced activation of human monocytic cells via modulating transmembrane TNF-alpha-mediated 'reverse signaling'. Xin L, Wang J, Zhang H, Shi W, Yu M, Li Q, Jiang X, Gong F, Gardner K, Li QQ, Li Z. Int J Mol Med; 2006 Nov 15; 18(5):885-92. PubMed ID: 17016618 [Abstract] [Full Text] [Related]
30. Enhanced effects of monoclonal antibody carboplatin immunoconjugates uptake and anti-tumor effects with angiotensin II and tumor necrosis factor. Takeda A, Miyoshi T, Shimada H, Ochiai T, Isono K. J Chemother; 1999 Apr 15; 11(2):137-43. PubMed ID: 10326745 [Abstract] [Full Text] [Related]
31. Multiple cytokine interactions regulate Ly-6E antigen expression: cooperative Ly-6E induction by IFNs, TNF, and IL-1 in a T cell lymphoma and in its induction-deficient variants. Altmeyer A, Staruch MJ, Cofano F, Landolfo S, Dumont FJ. Cell Immunol; 1991 Nov 15; 138(1):94-107. PubMed ID: 1717166 [Abstract] [Full Text] [Related]
33. Effect of interleukin-2 on biodistribution of monoclonal antibody in tumor and normal tissues in mice bearing SL-2 thymoma. Schultz KR, Badger CC, Dombi GW, Greenberg PD, Bernstein ID. J Natl Cancer Inst; 1992 Jan 15; 84(2):109-13. PubMed ID: 1735876 [Abstract] [Full Text] [Related]
34. Anti-Ly-6E.1-monoclonal-antibody-mediated augmentation of interleukin-2-dependent generation of natural killer cell activity from mouse bone marrow cells. Lu L, Herberman RB, DeLeo AB. Nat Immun; 1994 Jan 15; 13(6):315-30. PubMed ID: 7894202 [Abstract] [Full Text] [Related]
38. Production of monoclonal antibodies against MM antigen: the serologic identification of MM antigen with Ly-6.2 alloantigen. Seto M, Takahashi T, Tanimoto M, Nishizuka Y. J Immunol; 1982 Jan 15; 128(1):201-5. PubMed ID: 6976371 [Abstract] [Full Text] [Related]